
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group is well positioned for continued growth with its proprietary Organ Care System (OCS) technology and solid financial guidance for the next fiscal year, including expected revenue growth of 20-25% and gross margins of 60%. The company also reported strong Q4 results, beating key metrics and indicating potential for even stronger growth in the future. Key points from the call highlight potential future revenue drivers, including expansion of the OCS platform and investments in the OUS franchise. With a strong track record and a potential to beat consensus estimates, TransMedics Group presents a compelling investment opportunity.
Bears say
TransMedics Group is facing challenges in conducting clinical trials as the maker of the Styrofoam coolers used for comparison is worried about the impact on their business; however, management remains confident in the trials enrolling successfully. The October 2025 SRTR data reflects positive transplant volumes and we anticipate continued growth in the coming months; therefore, we have raised our price target to $166.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares